Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Jianxing He, Chunxia Su, Wenhua Liang, Shidong Xu, Lin Wu, Xiangning Fu, Xu Dong Zhang, Di Ge, Qun Chen, Weimin Mao, Lin Xu, Chun Chen, Bing Hu, Guoguang Shao, Jian Hu, Jian Zhao, Xiaoqing Liu, Zhidong Liu, Zheng Wang, Zemin Xiao, Taiqian Gong, Wen Lin, Xingya Li, Feng Ye, Yang Liu, Haitao Ma, Yunchao Huang, Jianying Zhou, Zhong Lin Wang, Junke Fu, Lieming Ding, Li Mao, Caicun Zhou (2021). Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. , 9(9), DOI: https://doi.org/10.1016/s2213-2600(21)00134-x.
